Related Experiment Video
Updated: May 28, 2026
03:45
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Genetics of Behçet's Disease.
1Department of Dermatology, Faculty of Medicine, Mersin University, 33079 Mersin, Turkey.
Pathology Research International
|October 21, 2011
Summary
Genetic factors significantly influence Behçet's disease (BD) susceptibility. The Human Leukocyte Antigen B51 (HLA-B51) is a key genetic marker, with other genetic associations also playing a role in disease development.
Area of Science:
- Immunogenetics
- Rheumatology
- Systemic Inflammatory Disorders
Background:
- Behçet's disease (BD) is a systemic inflammatory condition marked by recurrent oral/genital ulcers and ocular inflammation.
- Genetic predisposition is recognized as a significant factor in BD susceptibility, evidenced by its unique geographical distribution and familial aggregation.
- The Human Leukocyte Antigen B51 (HLA-B51) subtype is the most established genetic marker for BD, particularly in Silk Road regions.
Purpose of the Study:
- To review and synthesize findings from Human Leukocyte Antigen (HLA) and non-HLA genetic association studies in Behçet's disease.
- To highlight the role of genetic factors in BD susceptibility and severity.
Main Methods:
- Review of existing genome-wide association studies (GWAS) and genetic polymorphism studies.
- Analysis of established genetic markers, including HLA-B51.
- Examination of geographical distribution and familial aggregation patterns.
Main Results:
- HLA-B51 (specifically the B510101 subtype) is strongly associated with BD in populations along the Silk Road.
- Recent GWAS and polymorphism studies have identified additional genetic associations contributing to BD susceptibility and/or severity.
- Genetic factors are confirmed as a major determinant in the etiology of Behçet's disease.
Conclusions:
- Genetic predisposition, particularly HLA-B51, plays a crucial role in Behçet's disease.
- Non-HLA genetic factors likely contribute to the complex genetic architecture of BD.
- Further research into genetic associations can elucidate BD pathogenesis and inform potential therapeutic strategies.
Related Concept Videos
01:35Pedigree Analysis
Overview
01:11Genetic Lingo
Overview
01:43Incomplete Dominance
Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...